Epithalon vs SS-31
Research Verdict
SS-31 is the stronger research reference for the stated comparison criteria. Elamipretide has accelerated FDA approval for a narrow Barth-syndrome population; epithalon has no independent or regulatory evidence of comparable quality.
Quick Answers
Which is better, Epithalon or SS-31?
SS-31 is the stronger research reference for the stated comparison criteria. Elamipretide has accelerated FDA approval for a narrow Barth-syndrome population; epithalon has no independent or regulatory evidence of comparable quality.
What is the key difference between Epithalon and SS-31?
SS-31 targets mitochondrial cardiolipin for cardiac energy metabolism; epithalon targets telomere biology for longevity - fundamentally different mechanisms and applications.
Evidence Comparison
Elamipretide: FDA accelerated approval for Barth syndrome patients weighing at least 30 kg, based on a 12-patient program with negative randomized primary endpoints and supportive muscle-strength/open-label findings. Epithalon: small Russian cohort studies without independent replication or FDA review. Elamipretide has the stronger evidence despite important limitations.
Evidence Context Favoring Epithalon
Longevity/telomere research; accepting that all evidence comes from a single Russian research group.
Evidence Context Favoring SS-31
Barth syndrome or cardiolipin-targeted mitochondrial research; the approval does not establish benefit for longevity or heart failure.
Side-by-Side Snapshot
| Evidence grade | Epithalon: Level C SS-31: Level B |
|---|---|
| Research status | Epithalon: Preclinical SS-31: FDA Approved |
| Primary category | Epithalon: Anti-Aging & Longevity SS-31: Anti-Aging & Longevity |
| Cited studies | Epithalon: 2 SS-31: 6 |